Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets ExpertiseGlobeNewsWire • 10/14/26
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of DirectorsGlobeNewsWire • 09/23/26
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving PremarketBenzinga • 09/16/26
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T PlatformGlobeNewsWire • 09/15/26
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 09/08/26
Tempest Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/26
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-TGlobeNewsWire • 07/21/26
Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026GlobeNewsWire • 07/15/26
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsGlobeNewsWire • 06/04/26
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross ProceedsGlobeNewsWire • 05/29/26
Tempest Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/26
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingGlobeNewsWire • 04/29/26
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TGlobeNewsWire • 04/22/26
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsGlobeNewsWire • 04/14/26
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026GlobeNewsWire • 03/11/26
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026GlobeNewsWire • 02/25/26
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T AssetsGlobeNewsWire • 02/11/26
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T AssetsGlobeNewsWire • 02/04/26
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to StockholdersGlobeNewsWire • 01/20/26
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 11/26/25